Embelin, a potent, nonpeptidic cell-permeable inhibitor of X-linked inhibitor of apoptosis protein (XIAP), exerts anti-tumor effects by limiting IL-6/STAT3 activation and the Th17 immune response in GBs [68]. Here, STAT3 is linked to neoplasm.